Production (Stage)
XORTX Therapeutics Inc.
XRTX.V
TSX
03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
---|---|---|---|---|---|
Net Income | 70.31% | -53.53% | 90.09% | 79.69% | 51.15% |
Total Depreciation and Amortization | 5.71% | -16.18% | -16.32% | -26.13% | -13.44% |
Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
Total Other Non-Cash Items | -83.76% | 83.04% | -365.73% | -106.52% | 41.09% |
Change in Net Operating Assets | 216.04% | 111.33% | 97.30% | 239.78% | -249.00% |
Cash from Operations | 44.12% | 44.12% | 54.03% | 49.87% | 39.61% |
Capital Expenditure | -- | -- | 100.00% | 100.00% | 92.83% |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | -43.84% | 7.60% | -2.29% | 30.60% | 31.85% |
Cash from Investing | -35.96% | 15.98% | 16.14% | 43.20% | 53.50% |
Total Debt Issued | -- | -- | -- | -- | -- |
Total Debt Repaid | -16.52% | -5.29% | -25.00% | -25.27% | -80.82% |
Issuance of Common Stock | -20.01% | 1,172,266.67% | -59.66% | -59.66% | -59.66% |
Repurchase of Common Stock | -- | -- | -- | -- | -- |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | 33.00% | -126.18% | -431.23% | -119.92% | -112.73% |
Cash from Financing | -16.20% | 869.73% | -73.47% | -70.84% | -70.89% |
Foreign Exchange rate Adjustments | -300.00% | -978.05% | -71.43% | 84.57% | 96.51% |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | 52.36% | 86.06% | 27.20% | 27.40% | 9.56% |